Failure of the oxytocin-induced increase in secretion of urinary kallikrein in young spontaneously hypertensive rats.

Majima M, Adachi K, Ohno T, Ogino M, Saito M, Kizuki K, Katsumata O, Yamashina S, Katori M

Japanese journal of pharmacology1 May 1996Cited by 6 (Europe PMC)

PMID8791167DOI10.1254/jjp.71.11PepBankPUB-08791167

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. No result from this study comes from people.

01AnimalAnimal study (in vivo)Efficacy outcome
In Wistar Kyoto rats, oxytocin infusion significantly increased urinary excretion of active kallikrein from basal levels at 15 and 30 min.
In plain wordsIn normal rats, oxytocin infusion raised kallikrein excretion in urine.
Peptide
Oxytocin
Outcome
IncreaseUrinary active kallikrein excretion in WKY rats
Study
ratn = 5
anesthetized spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY), 4 weeks old
Outcome group
Kidney function · Kidney and urinary
Studied dose
30 nmol/kg/30 min · infusion · 30 minAs given in this study (rat).
Measurements
Urinary active kallikrein
37.3 10(-2) x AU/15 min
WKY, 15 min
Urinary active kallikrein
50.7 10(-2) x AU/15 min
WKY, 30 min
Urinary active kallikrein
25.4 10(-2) x AU/15 min
WKY, basal
Source sentences
Summary
OT-infusion (30 nmol/kg/30 min) to WKY significantly increased urinary excretion of the active kallikrein from the basal levels (25.4 +/- 5.6 10(-2) x AU/15 min, n = 5) to 37.3 +/- 5.0 10(-2) x AU/15 min (P < 0.05, n = 5) and 50.7 +/- 17.1 10(-2) x AU/15 min (P < 0.05, n = 5) 15 and 30 min after the…
1 context sentence(design, population, supporting numbers)
Summary · context
Urinary kallikrein excretion during oxytocin (OT) infusion were studied in anesthetized (sodium pentobarbital, 50 mg/kg, i.p.) young (4-weeks-old) spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY).
Report a problemFND-0879116701
02AnimalAnimal study (in vivo)Efficacy outcome
In spontaneously hypertensive rats, oxytocin infusion did not increase urinary excretion of active kallikrein.
In plain wordsIn rats with high blood pressure, oxytocin infusion did not raise kallikrein excretion in urine.
Peptide
Oxytocin
Outcome
No significant changeUrinary active kallikrein excretion in SHR
Study
ratn: not reported in source
anesthetized spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY), 4 weeks old
Outcome group
Kidney function · Kidney and urinary
Studied dose
30 nmol/kg/30 min · infusion · 30 minAs given in this study (rat).
Source sentences
Summary
In SHR, OT-infusion did not increase the urinary excretion of active kallikrein
1 context sentence(design, population, supporting numbers)
Summary · context
Urinary kallikrein excretion during oxytocin (OT) infusion were studied in anesthetized (sodium pentobarbital, 50 mg/kg, i.p.) young (4-weeks-old) spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY).
Report a problemFND-0879116702
03AnimalAnimal study (in vivo)Efficacy outcome
In spontaneously hypertensive rats, oxytocin infusion decreased urine volume.
In plain wordsIn rats with high blood pressure, oxytocin infusion reduced urine volume.
Peptide
Oxytocin
Outcome
DecreaseUrine volume in SHR
Study
ratn: not reported in source
anesthetized spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY), 4 weeks old
Outcome group
Kidney function · Kidney and urinary
Studied dose
30 nmol/kg/30 min · infusion · 30 minAs given in this study (rat).
Source sentences
Summary
but did decrease the urine volume and sodium excretion.
1 context sentence(design, population, supporting numbers)
Summary · context
Urinary kallikrein excretion during oxytocin (OT) infusion were studied in anesthetized (sodium pentobarbital, 50 mg/kg, i.p.) young (4-weeks-old) spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY).
Report a problemFND-0879116703
04AnimalAnimal study (in vivo)Efficacy outcome
In spontaneously hypertensive rats, oxytocin infusion decreased sodium excretion.
In plain wordsIn rats with high blood pressure, oxytocin infusion reduced sodium excretion in urine.
Peptide
Oxytocin
Outcome
DecreaseSodium excretion in SHR
Study
ratn: not reported in source
anesthetized spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY), 4 weeks old
Outcome group
Kidney function · Kidney and urinary
Studied dose
30 nmol/kg/30 min · infusion · 30 minAs given in this study (rat).
Source sentences
Summary
but did decrease the urine volume and sodium excretion.
1 context sentence(design, population, supporting numbers)
Summary · context
Urinary kallikrein excretion during oxytocin (OT) infusion were studied in anesthetized (sodium pentobarbital, 50 mg/kg, i.p.) young (4-weeks-old) spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY).
Report a problemFND-0879116704
05AnimalAnimal study (in vivo)Efficacy outcome
In Wistar Kyoto rats, kidney active kallikrein concentration was not changed by oxytocin infusion.
In plain wordsIn normal rats, oxytocin infusion did not change kallikrein levels in the kidney.
Peptide
Oxytocin
Outcome
No significant changeKidney active kallikrein concentration in WKY rats
Study
ratn: not reported in source
anesthetized spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY), 4 weeks old
Outcome group
Kidney function · Kidney and urinary
Studied dose
30 nmol/kg/30 min · infusion · 30 minAs given in this study (rat).
Source sentences
Summary
The concentration of the active kallikrein in the kidney of WKY was not changed by OT-infusion
1 context sentence(design, population, supporting numbers)
Summary · context
Urinary kallikrein excretion during oxytocin (OT) infusion were studied in anesthetized (sodium pentobarbital, 50 mg/kg, i.p.) young (4-weeks-old) spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY).
Report a problemFND-0879116705
06AnimalAnimal study (in vivo)Efficacy outcome
In spontaneously hypertensive rats, kidney active kallikrein concentration was slightly increased by oxytocin infusion.
In plain wordsIn rats with high blood pressure, oxytocin infusion slightly raised kallikrein levels in the kidney.
Peptide
Oxytocin
Outcome
IncreaseKidney active kallikrein concentration in SHR
Study
ratn: not reported in source
anesthetized spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY), 4 weeks old
Outcome group
Kidney function · Kidney and urinary
Studied dose
30 nmol/kg/30 min · infusion · 30 minAs given in this study (rat).
Source sentences
Summary
but that of SHR was slightly increased.
1 context sentence(design, population, supporting numbers)
Summary · context
Urinary kallikrein excretion during oxytocin (OT) infusion were studied in anesthetized (sodium pentobarbital, 50 mg/kg, i.p.) young (4-weeks-old) spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY).
Report a problemFND-0879116706
07AnimalAnimal study (in vivo)Efficacy outcome
In young rats given oxytocin infusion, the kidney concentration of active kallikrein was significantly higher in spontaneously hypertensive rats than in Wistar Kyoto rats.
In plain wordsIn young rats given oxytocin, kidney kallikrein was higher in rats with high blood pressure than in normal rats.
Peptide
Oxytocin
Outcome
IncreaseKidney active kallikrein concentration in SHR versus WKY rats during oxytocin infusion
Study
ratn: not reported in source
anesthetized spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY), 4 weeks old
Comparator
Wistar Kyoto rats
Outcome group
Kidney function · Kidney and urinary
Studied dose
30 nmol/kg/30 min · infusion · 30 minAs given in this study (rat).
Source sentences
Summary
The OT-infusion resulted in significantly higher concentrations of the active kallikrein in SHR kidney than in WKY kidney.
1 context sentence(design, population, supporting numbers)
Summary · context
Urinary kallikrein excretion during oxytocin (OT) infusion were studied in anesthetized (sodium pentobarbital, 50 mg/kg, i.p.) young (4-weeks-old) spontaneously hypertensive rats (SHR) and Wistar Kyoto rats (WKY).
Report a problemFND-0879116707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 20:03 UTC
Study results updated
Version 1
9 Oct 2026, 02:52 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.